The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Celgene is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of CELG and the rest of the Medical group's stocks.
Celgene is a member of the Medical sector. This group includes 845 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CELG is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CELG's full-year earnings has moved 4.95% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that CELG has returned about 47.70% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 4.45% on average. As we can see, Celgene is performing better than its sector in the calendar year.
Breaking things down more, CELG is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have gained 4.26% this year, meaning that CELG is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CELG. The stock will be looking to continue its solid performance.
Image: Bigstock
Is Celgene (CELG) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Celgene is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of CELG and the rest of the Medical group's stocks.
Celgene is a member of the Medical sector. This group includes 845 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CELG is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for CELG's full-year earnings has moved 4.95% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that CELG has returned about 47.70% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 4.45% on average. As we can see, Celgene is performing better than its sector in the calendar year.
Breaking things down more, CELG is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #77 in the Zacks Industry Rank. On average, stocks in this group have gained 4.26% this year, meaning that CELG is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CELG. The stock will be looking to continue its solid performance.